Literature DB >> 2895516

Rift Valley fever virus transmission by different Egyptian mosquito species.

A M Gad1, M M Hassan, S el Said, M I Moussa, O L Wood.   

Abstract

4 Egyptian mosquito species were tested for their ability to transmit the Egyptian ZH-501 strain of Rift Valley fever virus (RVFV) to golden Syrian hamsters. Culex (Cx.) antennatus was the most efficient vector, showing a 37.5% transmission rate following a hamster blood meal containing 10 suckling mouse intracerebral 50% lethal doses (SMILD50) per ml. Fully engorged mosquitoes of this species showed an infection rate of 85% with the mean viral titres of transmitting mosquitoes 100-fold higher than non-transmitters. Autogenous and anautogenous populations of Aedes (Ae.) caspius were tested separately, and the transmission rates were 23.1% and 9.7% respectively, following feeding on hamsters with similar levels of viraemia. Two anopheline species, Anopheles (An.) multicolor and An. pharoensis, showed 12.5% and 3.5% transmission rates under similar conditions. In these 3 species infection rates exceeded 75% and mosquitoes transmitting had a higher average titre than those not transmitting.

Entities:  

Mesh:

Year:  1987        PMID: 2895516     DOI: 10.1016/0035-9203(87)90460-3

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  14 in total

1.  Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein.

Authors:  Sonja R Gerrard; Stuart T Nichol
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep.

Authors:  Bonto Faburay; William Wilson; D Scott McVey; Barbara S Drolet; Hana Weingartl; Daniel Madden; Alan Young; Wenjun Ma; Juergen A Richt
Journal:  Vector Borne Zoonotic Dis       Date:  2013-08-20       Impact factor: 2.133

Review 3.  A review of mosquitoes associated with Rift Valley fever virus in Madagascar.

Authors:  Luciano M Tantely; Sébastien Boyer; Didier Fontenille
Journal:  Am J Trop Med Hyg       Date:  2015-03-02       Impact factor: 2.345

4.  A statistical model of Rift Valley fever activity in Egypt.

Authors:  John M Drake; Ali N Hassan; John C Beier
Journal:  J Vector Ecol       Date:  2013-12       Impact factor: 1.671

5.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

6.  Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon.

Authors:  Claire Marie Filone; Sheri L Hanna; M Cecilia Caino; Shelly Bambina; Robert W Doms; Sara Cherry
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

7.  A Stochastic Model to Study Rift Valley Fever Persistence with Different Seasonal Patterns of Vector Abundance: New Insights on the Endemicity in the Tropical Island of Mayotte.

Authors:  Lisa Cavalerie; Maud V P Charron; Pauline Ezanno; Laure Dommergues; Betty Zumbo; Eric Cardinale
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

8.  Risk analysis of inter-species reassortment through a Rift Valley fever phlebovirus MP-12 vaccine strain.

Authors:  Hoai J Ly; Nandadeva Lokugamage; Shoko Nishiyama; Tetsuro Ikegami
Journal:  PLoS One       Date:  2017-09-19       Impact factor: 3.240

9.  Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins.

Authors:  Li Liu; Cristina C P Celma; Polly Roy
Journal:  Virol J       Date:  2008-07-18       Impact factor: 4.099

10.  The transmission potential of Rift Valley fever virus among livestock in the Netherlands: a modelling study.

Authors:  Egil A J Fischer; Gert-Jan Boender; Gonnie Nodelijk; Aline A de Koeijer; Herman J W van Roermund
Journal:  Vet Res       Date:  2013-07-22       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.